Linked Life Data

19186240

Source:http://linkedlifedata.com/resource/pubmed/id/19186240

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2009-2-2
pubmed:abstractText
This article covers the multidisciplinary treatment of primary melanoma. Excision margins and the need for sentinel lymphadenectomy are mainly dictated by the Breslow thickness although exceptions to this dictum do exist. Interferon is the only FDA approved adjuvant therapy for high risk melanoma although its overall survival benefit is minimal. Trials examining different doses or duration of interferon therapy have not demonstrated any promising survival data so far. There have been several randomized vaccine trials for melanoma but none have shown an overall survival benefit. Research into T-cell regulation continues and will hopefully bring promise for the future of melanoma treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0039-6109
pubmed:author
pubmed:issnType
Print
pubmed:volume
89
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
267-81, xi
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Multidisciplinary treatment of primary melanoma.
pubmed:affiliation
Department of Surgery, Northwestern University Feinberg School of Medicine, NorthShore University HealthSystem, Evanston Hospital-Walgreen Bldg Suite 2507, 2650 Ridge Ave, Evanston, IL 60201, USA. kyao@northshore.org
pubmed:publicationType
Journal Article, Review